Best of ASCO® Montreal 2024: Breast Cancer Updates – Dr. Jamil Asselah
OR
Co-Chairs
Dr. Jamil Asselah
Dr. Kim Ma
Speakers
Dr. Jamil Asselah
Studies/trials discussed:
- Baseline characteristics and efficacy endpoints for patients with node negative HR+ HER2early breast cancer: NATALEE trial.
- A-BRAVE trial: A phase III randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant chemotherapy.
- Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial.
- Trastuzumab deruxtecan (T-DXd) vs physician’s choice of chemotherapy (TPC) in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor 2 (HER2)-low or HER2-ultralow metastatic breast cancer (mBC) with prior endocrine therapy (ET): Primary results from DESTINY-Breast06 (DB-06).
